The Rossy Cancer Network (RCN) - a partnership between the Â鶹´«Ã½ÍøÕ¾ Health Centre, Jewish General Hospital, St. Mary’s Hospital, and Â鶹´«Ã½ÍøÕ¾ - identified that existing clinical trial databases often provided inaccurate or hard-to-access information about active trials across the network. To remedy this, the RCN launched a Clinical Trials Program whose first objective was to build this dedicated website powered by a unified clinical trial management platform. This platform offers real-time updates from clinical research associates and managers, resulting in an accurate, searchable database of all active trials across the network.
Clinical Trials Across the Rossy Cancer Network
The RCN brings together over 150 dedicated oncology clinical research professionals including oncologists, research nurses, study coordinators, and trial managers - united by a commitment to advancing cancer care. Our mission is to provide patients with access to today’s most innovative treatments while driving research that will shape the therapies of the future. Each year, we enroll more than 700 patients in clinical trials, offering access to breakthrough therapies and generating critical data for both pharmaceutical and investigator-led studies.
- Rossy Cancer Network Clinical Trials Team
- Â鶹´«Ã½ÍøÕ¾ Health Centre
- Jewish General Hospital
- St. Mary’s Hospital
Rossy Cancer Network Clinical Trials Team
Dr. Ramy Saleh
Project Lead
Â鶹´«Ã½ÍøÕ¾ Health Centre
Dr. Ramy Saleh is a medical oncologist and Associate Professor at Â鶹´«Ã½ÍøÕ¾, specializing in genitourinary malignancies and sarcomas. He serves as the Medical Director of the Phase I Medical Oncology Unit at the Research Institute of the Â鶹´«Ã½ÍøÕ¾ Health Centre, focusing on early-stage clinical trials and innovative cancer treatments.
Dr. Wilson Miller
Project Lead
Jewish General Hospital
Dr. Wilson H. Miller is a Professor in the Departments of Medicine and Oncology at Â鶹´«Ã½ÍøÕ¾ and serves as the Director of the Clinical Research Unit at the Jewish General Hospital's Lady Davis Institute for Medical Research. His research focuses on molecular oncology, therapeutic resistance, and the development of novel anti-cancer therapies.
Dr. Adrian Langleben
Project Lead
St. Mary’s Hospital
Dr. Adrian Langleben is an Associate Professor of Oncology at Â鶹´«Ã½ÍøÕ¾ and serves as the Director of the Oncology Program at St. Mary’s Hospital Center, where he leads clinical trials and cancer care initiatives across the CIUSSS de l’Ouest-de-l’Île-de-Montréal network. His research focuses on solid tumors, including head and neck cancers and sarcomas, and he has played a pivotal role in advancements in lung cancer treatment through clinical trials involving immunotherapy.
Luca Petruccelli
Project Manager
Rossy Cancer Network
Luca is a Project Manager for the Rossy Cancer Network.
Â鶹´«Ã½ÍøÕ¾ Health Centre
Dr. Ramy Saleh
Centre for Innovative Medicine, Medical Director,
Oncology Research Program, Phase I Clinical Trial Unit
Dr. Ramy Saleh is a medical oncologist and Associate Professor at Â鶹´«Ã½ÍøÕ¾, specializing in genitourinary malignancies and sarcomas. He serves as the Medical Director of the Phase I Medical Oncology Unit at the Research Institute of the Â鶹´«Ã½ÍøÕ¾ Health Centre, focusing on early-stage clinical trials and innovative cancer treatments.
Dr. Lucy Gilbert
Women’s Health Research Unit, Director
Dr. Lucy Gilbert is a Professor in the Departments of Obstetrics & Gynecology and Oncology at Â鶹´«Ã½ÍøÕ¾, serving as the Director of Gynecologic Oncology and the Women's Health Research Unit at the Â鶹´«Ã½ÍøÕ¾ Health Centre (MUHC), and is also the Â鶹´«Ã½ÍøÕ¾ Chair of the Gerald Bronfman Department of Oncology, Faculty of Medicine and Health Sciences. Her research focuses on the early detection of gynecologic cancers.
Phuong-Nam Nathalie Nguyen
Women’s Health Research Unit, Manager
Phuong-Nam Nathalie Nguyen is the Clinical Research Manager for the Women's Health Research Unit (WHRU) at the Â鶹´«Ã½ÍøÕ¾ Health Centre. The WHRU consists of a team of 7 research nurses and 7 study coordinators who specialize in the conduct of Phase 1 to 3 gynecologic oncology clinical trials.
Dr. Michael Sebag
Cancer Research Program Lead, Hematological Malignancies
Dr. Michael Sebag is an Associate Professor in the Department of Medicine at Â鶹´«Ã½ÍøÕ¾ and a hematologist at the Â鶹´«Ã½ÍøÕ¾ Health Centre. His research focuses on multiple myeloma, including the tumor microenvironment and drug development, aiming to improve patient outcomes through clinical trials and innovative therapies.
Dr. Victoria Korsos
Cancer Research Program Co-Lead, Hematological Malignancies
Dr. Victoria Korsos is an Assistant Professor in the Division of Hematology at Â鶹´«Ã½ÍøÕ¾ and a clinician-researcher at the Â鶹´«Ã½ÍøÕ¾ Health Centre, specializing in cellular therapies for multiple myeloma and lymphoma. With advanced training in cancer immunotherapy from Memorial Sloan Kettering Cancer Center, her research focuses on improving quality of life and establishing end-of-life care markers for patients with blood cancers.
Nancy Renouf
Cancer Research Program Manager, Hematological Malignancies
Nancy Renouf is the Clinical Research Manager for hematological cancer trials at the Â鶹´«Ã½ÍøÕ¾ Health Centre, where she oversees studies focused on novel therapies for conditions such as multiple myeloma. She plays a key role in advancing patient-centered research and ensuring the smooth operation of clinical trial activities within the hematology program.
Dr. Nathaniel Bouganim
Cancer Research Program, Lead, Breast Cancer
Dr. Nathaniel Bouganim is an Assistant Professor of Oncology at Â鶹´«Ã½ÍøÕ¾ and Division Director of Medical Oncology at the Â鶹´«Ã½ÍøÕ¾ Health Centre (MUHC). He specializes in breast, head and neck, and hepatobiliary cancers, and directs the MUHC’s Oncology In-Patient Teaching Unit. An active clinical researcher, he leads multiple phase 1–3 trials and is a founding member of the McPeak-Sirois scientific committee. He also contributes to provincial oncology guidelines through CEPO and serves as a breast cancer expert for INESSS.
Dr. Jamil Asselah
Cancer Research Program, Co-Lead, Breast Cancer
Dr. Jamil Asselah is an Associate Professor in Oncology at Â鶹´«Ã½ÍøÕ¾ and a medical oncologist at the MUHC’s Cancer Research Program, where he leads several pivotal clinical trials in breast cancer. He also serves as President of the McPeak Sirois Group’s Executive Scientific Committee and co-developed the OPAL patient portal—efforts recognized by the Quebec Breast Cancer Foundation and National Bank for innovation in patient care.
Stelliana Moreno
Cancer Research Program Manager, Breast Cancer
Stelliana Moreno is the Clinical Research Manager for breast cancer. With certifications in clinical research coordination and project management, she plays a pivotal role in site operations, regulatory compliance, and stakeholder collaboration across sponsors, CROs, and ethics boards.
Dr. Christina Tsien
Cancer Research Program, Radiation Oncology
Dr. Christina Tsien is a Professor of Radiation Oncology at Â鶹´«Ã½ÍøÕ¾ and an investigator at the Research Institute of the Â鶹´«Ã½ÍøÕ¾ Health Centre. She specializes in central nervous system malignancies, with clinical interests in proton therapy and stereotactic radiosurgery.
Marianna Perna
Cancer Research Program Manager, Radiation Oncology
Marianna Perna is the Clinical Research Manager for Radiation Oncology, where she oversees oncology trials across multiple disease sites including breast and genitourinary cancers. A certified clinical research professional (CCRP, CCRC), she plays a pivotal role in coordinating multi-phase studies, ensuring regulatory compliance, and facilitating collaboration among investigators, sponsors, and ethics boards.
Jewish General Hospital
Dr. Wilson Miller
Clinical Research Unit Director
Dr. Wilson H. Miller is a Professor in the Departments of Medicine and Oncology at Â鶹´«Ã½ÍøÕ¾ and serves as the Director of the Clinical Research Unit at the Jewish General Hospital's Lady Davis Institute for Medical Research. His research focuses on molecular oncology, therapeutic resistance, and the development of novel anti-cancer therapies.
Dr. Sarit Assouline
Clinical Research Unit Associate Director
Dr. Sarit Assouline is a Professor of Medicine at Â鶹´«Ã½ÍøÕ¾ and a hematologist-oncologist at the Jewish General Hospital specializing in lymphomas and chronic lymphocytic leukemia. She leads and collaborates on numerous clinical trials, with a focus on developing targeted therapies and improving outcomes for patients.
Adele Casini
Clinical Research Unit Head of Operations
Adele Cascini is the Manager of the Clinical Research Unit at the Jewish General Hospital, where she has played a key role in advancing oncology research and clinical trial operations for over two decades. Her leadership has been central to ensuring rigorous study oversight and delivering patient-centered care in cancer research.
Dr. Petr Kavan
Clinical Research Program Scientific Director
Dr. Petr Kavan is an Associate Professor of Oncology at Â鶹´«Ã½ÍøÕ¾ and a medical oncologist at the Jewish General Hospital. He serves as the Director of Â鶹´«Ã½ÍøÕ¾'s Adolescent and Young Adult Oncology (AYAO) Program, focusing on cancers affecting this demographic. His research interests include gastrointestinal oncology, with a particular emphasis on colorectal and pancreatic cancers, as well as neuroendocrine tumors.
Dr. Jean-Francois Boileau
Breast Research Group Scientific Director
Dr. Jean-François Boileau is an Associate Professor of Surgery and Oncology at Â鶹´«Ã½ÍøÕ¾ and a surgical oncologist at the Jewish General Hospital. He directs the Breast Clinical Trials Group and is a founding member of the Quebec McPeak-Sirois Clinical Trials Consortium. His research focuses on breast cancer, particularly neoadjuvant therapy and axillary management, and includes leadership on trials such as SN FNAC, PALLET, KRISTINE, and KEYNOTE-522.
Aline Mamo
Clinical Research Program, Breast Research Group, Research Nuclear Medicine Managing Director
Aline Mamo is the Administrative Director of the Phase III Clinical Research Program at the Jewish General Hospital (JGH). With a PhD and postdoctoral training from Université de Montréal and Â鶹´«Ã½ÍøÕ¾, she has contributed to clinical research in colorectal, pancreatic, brain, breast, and genitourinary (GU) cancers. She also leads clinical research in nuclear medicine and oversees Theranostics trials in GU cancers through a strong collaboration with the JGH Nuclear Medicine department. For breast cancer, she manages trials in both early-stage and metastatic disease.
Dr. Tamim Niazi
Director, Radiation Oncology
Dr. Tamim Niazi is an Associate Professor in the Department of Oncology at Â鶹´«Ã½ÍøÕ¾, specializing in radiation oncology for genitourinary cancers, particularly prostate cancer. He has led numerous national Phase II and III clinical trials and holds leadership roles in several national clinical and quality assurance groups, with over 80 peer-reviewed publications.
Dr. Boris Bahoric
Associate Director, Radiation Oncology
Dr. Boris Bahoric is an Assistant Professor at Â鶹´«Ã½ÍøÕ¾ and Associate Director of the Division of Radiation Oncology, with clinical and research expertise across several cancer disease sites. His research focuses on radiotherapy for gynecological and genitourinary malignancies, as well as brachytherapy for gynecological tumors, prostate, breast, and head and neck cancers.
Dr. Té Vuong
Director, Gastrointestinal Radiation Oncology
Dr. Te Vuong is a Professor of Radiation Oncology at Â鶹´«Ã½ÍøÕ¾ and a radiation oncologist at the Jewish General Hospital. She specializes in gastrointestinal cancers, with a focus on rectal cancer treatment and optimizing radiotherapy techniques to improve patient outcomes.
St. Mary’s Hospital
Dr. Adrian Langleben
Clinical Research Program Director
Dr. Adrian Langleben is an Associate Professor of Oncology at Â鶹´«Ã½ÍøÕ¾ and serves as the Director of the Oncology Program at St. Mary’s Hospital Center, where he leads clinical trials and cancer care initiatives across the CIUSSS de l’Ouest-de-l’Île-de-Montréal network. His research focuses on solid tumors, including head and neck cancers and sarcomas, and he has played a pivotal role in advancements in lung cancer treatment through clinical trials involving immunotherapy.